- PTAB · Oct 31, 2014 · IPR2013-00450 · APJ Scott E Kamholz · IPR · Order
The Board granted the parties’ joint motion to terminate IPR2013-00450 as to all parties and granted confidential treatment of the settlement agreement.
RulingsOther- PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Granted
“In view of the parties’ settlement agreement made in connection with the termination in accordance with 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(b), we determine that it is appropriate to terminate the involvement of Petitioner. Moreover, we determine that it also is appropriate to terminate the proceeding with respect to Patent Owner, because we have not yet decided the merits of this proceeding. As a result, it is appropriate to enter judgment in the form of termination. See 37 C.F.R. § 42.2. Accordingly, it is ORDERED that the joint motion to terminate IPR2013-00450 is granted, and this proceeding is hereby terminated as to all parties, including Petitioner Clio USA, Inc. and Patent Owner The Procter & Gamble Company; and” slip op. at 2
NonePatents in suitUS 7,122,199 - PTAB · Oct 31, 2014 · IPR2013-00448 · APJ Scott E Kamholz · IPR · Order
The Board granted the parties’ joint motion and terminated the proceeding as to all parties before deciding the merits.
RulingsOther- PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Granted
“The parties filed a joint motion to terminate the instant proceeding (Paper 55 (“Mot.”)), and a true copy of their written settlement agreement (Ex. 2037) made in connection with the termination, in accordance with 35 U.S.C. § 317 and 37 C.F.R. § 42.74(b). The parties also jointly requested that their settlement agreement be treated as business confidential information under 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c). Paper 56. For the reasons provided below, the joint motion to terminate is granted. The joint request that the settlement agreement be treated as business confidential information is also granted.” slip op. at 2
NonePatents in suitUS 5,891,453 - PTAB · Oct 31, 2014 · IPR2013-00438 · APJ Scott E Kamholz · IPR · Order
The Board granted the parties’ joint motion to terminate IPR2013-00438 as to all parties and granted confidential treatment of the settlement agreement; it did not decide patentability.
RulingsOther- PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Granted
“The parties filed a joint motion to terminate the instant proceeding (Paper 54 (“Mot.”)), and a true copy of their written settlement agreement (Ex. 2038) made in connection with the termination, in accordance with 35 U.S.C. § 317 and 37 C.F.R. § 42.74(b). The parties also jointly requested that their settlement agreement be treated as business confidential information under 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c). Paper 55. For the reasons provided below, the joint motion to terminate is granted. The joint request that the settlement agreement be treated as business confidential information is also granted.” slip op. at 2
NonePatents in suitUS 5,894,017 - PTAB · Oct 28, 2014 · IPR2013-00266 · APJ Christopher L Crumbley · IPR · Final written decision
The Board denied entry of substitute claims 20–26 as obvious, and granted cancellation of challenged claims 1, 2, 4, 11, 12, 17, 18, and 19.
RulingsFinal written decision- Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)Plain and ordinary meaningDecided for petitioner
“1. the cleavable linker and the protecting group are cleavable under identical conditions Proposed substitute claim 20 recites, inter alia, “a base that is linked to a detectable label via a cleavable linker,” a “protecting group attached via the 3' oxygen atom” of the nucleotide, and a step of “removing the label and the protecting group of the nucleotide . . . under a single set of chemical cleavage conditions.” Mot. 2 (emphasis added). These limitations are similar to those present in original claim 1, which we construed in our Decision on Institution. Specifically, we construed removal of the label and the protecting group under a single set of conditions “to mean what its plain language indicates: removal of the label and the protecting group under a single set of conditions.” Dec. 6. Neither of the parties contested this construction subsequent to institution, and we discern no reason to modify our initial construction for the purposes of this decision. Proposed claim 20 also requires that the cleavable linker comprise a disulfide linkage, but does not specify the protecting group. Thus, “a single set of chemical cleavage conditions,” under the broadest reasonable interpretation standard, limits the structure of the protecting group to one which can be cleaved under the same conditions as a disulfide linkage, but does not require a specific structure, such as a disulfide linkage.” slip op. at 8
- Obviousness (§103) › Motivation to combine / reasonable expectation of successMotivation foundReasonable expectation foundUnpatentable
- Obviousness (§103) › Objective indicia / secondary considerations › NexusObjective indicia no nexusDecided for patent owner
“Illumina was essentially 100%. This is a significant and unexpected improvement over the disulfide cleavages of Ruby (~86%) and Herman (87%).” Ex. 2004 ¶ 84. There is no testimony, however, that the stated results were due to the claimed nucleotide rather than the reducing agent. While Dr. Romesberg refers to the “disulfide cleavage yield” as being unexpected, he does not testify that this yield was attributable to the claimed nucleotide configuration, rather than the reducing agent which performs the disulfide bond cleavage. Illumina has not distinguished the Vermaas results from the prior art by showing that the nucleotide is responsible for the disulfide yield, rather than it being a property of the disulfide bond and the yield being “the mere recognition” of the bond’s “latent properties,” which “does not render nonobvious an otherwise known invention.” Baxter, 952 F.2d at 392; In re Geisler, 116 F.3d 1465, 1468 (Fed. Cir. 1997). Absent such evidence, Illumina has not shown that the claimed subject matter possesses “unexpected results relative to the prior art.” Galderma Labs., LP v. Tolmar, Inc., 737 F3d 731, 738 (Fed. Cir. 2013). “The combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results.” KSR, 550 U.S. at 416.” slip op. at 28
- PTAB / AIA Trials › Motions to amend / substitute claimsMotion to amend granted in partGranted in part
“After considering all the evidence as a whole, we conclude that Illumina has not met its burden in showing that the proposed substitute claims are patentable over the prior art considered in this Decision. The Motion to Amend is DENIED to the extent that it requests entry of substitute claims 20–26.” slip op. at 28
Claim construction§ 103 obviousnesscites KSR · GrahamPatents in suitUS 8,158,346 - PTAB · Sep 12, 2014 · IPR2014-00464 · APJ Scott E Kamholz · IPR · Order
The Board granted the parties’ joint motion and terminated the proceeding as to all parties before deciding the merits.
RulingsOther- PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Granted
“The parties filed a joint motion to terminate the instant proceeding (Paper 13 (“Mot.”)), and a true copy of their written settlement agreement (Ex. 1015) made in connection with the termination, in accordance with 35 U.S.C. § 317 and 37 C.F.R. § 42.74(b). The parties also jointly requested that their settlement agreement be treated as business confidential information under 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c). Paper 14. For the reasons provided below, the joint motion to terminate is granted. The joint request that the settlement agreement be treated as business confidential information is also granted.” slip op. at 2
- Adverse judgmentOther
“In view of the parties’ settlement agreement made in connection with the instant proceeding in accordance with 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(b), we determine that it is appropriate to terminate the involvement of Petitioner. Moreover, in view of the early stage of this proceeding, and the absence of other proceedings involving the ’196 patent, we determine that it also is appropriate to terminate the proceeding with respect to Patent Owner. As a result, it is appropriate to enter judgment in the form of termination. See 37 C.F.R. § 42.2. Accordingly, it is ORDERED that the joint motion to terminate IPR2014-00464 is granted, and this proceeding is hereby terminated as to all parties, including Petitioner Mohawk Resources Ltd., and Patent Owner Vehicle Service Group, LLC; and” slip op. at 2
NonePatents in suitUS 6,983,196 - PTAB · Sep 12, 2014 · IPR2014-00551 · APJ Scott E Kamholz · IPR · Order
The Board granted the parties’ joint motion and terminated the proceeding as to all parties because they settled and the proceeding was at an early stage.
RulingsOther- PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Granted
“While the parties may agree to settle their issues related to the involved patent, the Board is not a party to the settlement and may determine independently any question of patentability. 37 C.F.R. § 42.74(a).” slip op. at 2
- Adverse judgmentOther
“In view of the parties’ settlement agreement made in connection with the termination in accordance with 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(b), we determine that it is appropriate to terminate the involvement of Petitioner. Moreover, we determine that it also is appropriate to terminate the proceeding with respect to Patent Owner, because of the early stage of the proceeding. As a result, it is appropriate to enter judgment in the form of termination. See 37 C.F.R. § 42.2. Accordingly, it is ORDERED that the joint motion to terminate IPR2013-00551 is granted, and this proceeding is hereby terminated as to all parties, including Petitioner Apex Medical Corp. and Patent Owner ResMed Limited; and” slip op. at 3
None - PTAB · Sep 12, 2014 · IPR2013-00516 · APJ Scott E Kamholz · IPR · Order
The Board granted the parties’ joint motion and terminated IPR2013-00516 as to all parties before deciding patentability.
RulingsOther- PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Granted
“In view of the parties’ settlement agreement made in connection with the termination in accordance with 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(b), we determine that it is appropriate to terminate the involvement of Petitioner. Moreover, we determine that it also is appropriate to terminate the proceeding with respect to Patent Owner, because we have not yet decided the merits of this proceeding, and the record is not yet closed. As a result, it is appropriate to enter judgment in the form of termination. See 37 C.F.R. § 42.2. Accordingly, it is ORDERED that the joint motion to terminate IPR2013-00516 is granted, and this proceeding is hereby terminated as to all parties, including Petitioner Apex Medical Corp. and Patent Owner ResMed Limited; and” slip op. at 3
NonePatents in suitUS 7,997,267 - PTAB · Sep 12, 2014 · IPR2013-00512 · APJ Scott E Kamholz · IPR · Order
The Board granted the joint motion to terminate IPR2013-00512 as to all parties and dismissed Patent Owner’s motion to amend as moot.
RulingsOther- PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Granted
“The parties filed a joint motion to terminate the instant proceeding (Paper 37 (“Mot.”)) and a true copy of their written settlement agreement (Ex. 2041) made in connection with the termination, in accordance with 35 U.S.C. § 317 and 37 C.F.R. § 42.74(b). The parties also jointly requested that their settlement agreement be treated as business confidential information under 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c). Paper 36. For the reasons provided below, the joint motion to terminate is granted. The joint request that the settlement agreement be treated as business confidential information is also granted.” slip op. at 2
- PTAB / AIA Trials › Motions to amend / substitute claimsOther
“Patent Owner has already filed a Response (Paper 17) and Motion to Amend (Paper 18), and Petitioner has filed a Reply (Paper 31) and Opposition (Paper 32), but the record is not yet closed, and the Board has not yet decided the merits of this proceeding. The parties represent that the ’772 patent is the subject of an exclusion order issued in ITC investigation No. 337-TA-879, as well as a stayed district court action, ResMed Inc. et al v. Apex Medical Corp. et al., No. 8:13-cv-00498 (C.D. Cal.). Mot. 5-7. The parties further represent that these matters are covered by the settlement agreement. Id. at 6, 7. In view of the parties’ settlement agreement made in connection with the termination in accordance with 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(b), we determine that it is appropriate to terminate the involvement of Petitioner. Moreover, we determine that it also is appropriate to terminate the proceeding with respect to Patent Owner, because we have not yet decided the merits of this proceeding, and the record is not yet closed. As a result, it is appropriate to enter judgment in the form of termination. See 37 C.F.R. § 42.2.” slip op. at 2
NonePatents in suitUS 7,487,772 - PTAB · Sep 11, 2014 · IPR2013-00511 · APJ Scott E Kamholz · IPR · Order
The Board granted the joint motion to terminate IPR2013-00511 as to all parties before deciding the merits, and granted confidential treatment of the settlement agreement.
RulingsOther- PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Granted
“The parties filed a joint motion to terminate the instant proceeding (Paper 28 (“Mot.”)) and a true copy of their written settlement agreement (Ex. 2018) made in connection with the termination, in accordance with 35 U.S.C. § 317 and 37 C.F.R. § 42.74(b). The parties also jointly requested that their settlement agreement be treated as business confidential information under 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c). Paper 29. For the reasons provided below, the joint motion to terminate is granted. The joint request that the settlement agreement be treated as business confidential information is also granted.” slip op. at 2
NonePatents in suitUS 7,159,587 - PTAB · Sep 11, 2014 · IPR2013-00514 · APJ Scott E Kamholz · IPR · Order
The Board granted the joint motion and terminated IPR2013-00514 as to all parties before deciding the merits.
RulingsOther- PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Granted
“The parties filed a joint motion to terminate the instant proceeding (Paper 24 (“Mot.”)) and a true copy of their written settlement agreement (Ex. 2012) made in connection with the termination, in accordance with 35 U.S.C. § 317 and 37 C.F.R. § 42.74(b). The parties also jointly requested that their settlement agreement be treated as business confidential information under 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c). Paper 25. For the reasons provided below, the joint motion to terminate is granted. The joint request that the settlement agreement be treated as business confidential information is also granted.” slip op. at 2
NonePatents in suitUS 6,216,691
Holdings, summaries, rulings, issues, outcomes, winners and claim constructions shown for a decision were generated by a large language model reading the opinion. They are a guide to the decision, not the decision. Confirm every one against the court's own text before relying on it. Outcomes read from the patent owner’s side. Party names are extracted from the decision and are missing on about 900 short Director denials and scans, which carry the trial number instead.